Cargando…
SAT-476 Alemtuzumab Induced Graves Disease
Introduction: Immune reconstitution therapy (IRT) with the monoclonal antibody alemtuzumab (anti-CD 52) has been shown to be superior to β-interferon in relapsing-remitting multiple sclerosis. It can cause early hyper-population of immature B cells which increases the risk of autoimmune disorders. T...
Autores principales: | Caputi, Rafael C, Raj, Kavin, Jimenez-Zuluaga, Jose Nicolas, Patel, Sima, Luo, Hongxiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209673/ http://dx.doi.org/10.1210/jendso/bvaa046.745 |
Ejemplares similares
-
SAT476 A Case of Thyroid Hemiagenesis
por: Kachhadia, Palak, et al.
Publicado: (2023) -
SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020) -
An Unusual Etiology of Graves’ Disease: Alemtuzumab
por: Santiago Carrion, Ada Marie, et al.
Publicado: (2021) -
ODP523 Thyroid Storm in a Patient With Alemtuzumab Induced Graves’ Disease
por: AlShehri, Sara, et al.
Publicado: (2022) -
SUN-582 Peripartum Central Hypothyroidism: A Case to Consider
por: Caputi, Rafael, et al.
Publicado: (2019)